Effect of Scheduled Autologous Platelet-rich Plasma Guided Injection in the Healing Process of Critical-sized Maxillary Bony Defects After Surgical Excision of Non- Malignant Lesions: A Prospective Randomized Clinical Trial.
Effect of Scheduled Autologous Platelet-rich Plasma Guided Injection in the Healing Process of Critical-sized Maxillary Bony Defects After Surgical Excision of Non- Malignant Lesions: A Prospective Randomized Clinical Trial.
Scheduled autologous platelet-rich plasma guided injection is done in critical-sized maxillary bony defects after surgical excision of non- malignant lesions.
The study aims to detect the effect of scheduled autologous platelet-rich plasma- guided injection in the healing process of critical-sized maxillary bony defects after surgical removal of non-malignant lesions by using bone volumetric analysis and density measuring with cone beam computed tomography.
Inclusion Criteria:
Diagnosis: Non-malignant maxillary bony defects (e.g., benign tumors or cysts).
Health: Generally healthy participants who can tolerate surgery.
Platelet Function: No platelet disorders or blood-related conditions.
Willingness: Informed consent and ability to follow the protocol.
No Use of Blood Thinners: No current use of anticoagulants like aspirin.
Exclusion Criteria:
Malignant Lesions: Participants with cancer or pre-cancerous conditions.
Systemic Illness: Severe conditions (e.g., uncontrolled diabetes, autoimmune disorders).
Platelet Disorders: Low platelet count or bleeding disorders (e.g., hemophilia).
Infections: Active infections or inflammatory conditions (e.g., periodontal disease).
Pregnancy: Women who are pregnant or breastfeeding.
Recent Surgery/Trauma: Recent maxillary surgery or trauma.
Uncontrolled Medications: Use of blood thinners, NSAIDs, or immunosuppressive drugs.
Non-compliance: Unwillingness or inability to follow-up with the protocol.
Substance Abuse: Active drug or alcohol abuse.